>>Signaling Pathways>> Tyrosine Kinase>> EGFR>>TAS6417

TAS6417 (Synonyms: TAS6417; CLN-081)

Catalog No.GC32752

TAS6417(CLN-081)은 1.1-8.0 nM 범위의 IC50 값으로 EGFR 힌지 영역의 ATP 결합 부위에 고유한 스캐폴드 피팅이 있는 매우 효과적인 경구 활성 및 범 돌연변이 선택적 EGFR 티로신 키나제 억제제입니다.

Products are for research use only. Not for human use. We do not sell to patients.

TAS6417 Chemical Structure

Cas No.: 1661854-97-2

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$297.00
재고 있음
5mg
US$270.00
재고 있음
10mg
US$450.00
재고 있음
25mg
US$945.00
재고 있음
50mg
US$1,350.00
재고 있음
100mg
US$1,980.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

TAS6417 is an EGFR inhibitor and an efficacious drug candidate for patients with NSCLC, with IC50 values ranging from 1.1-8.0 nM.

TAS6417 inhibits the in vitro phosphorylation activity of EGFR and its mutants including an exon 20 insertion mutation, with IC50 values ranging from 1.1±0.1 to 8.0±1.1 nM. TAS6417 suppresses the growth of cells expressing exon 20 insertion mutations of the EGFR gene, with a GI50 value of 86.5±28.5 nM for LXF 2478L cells and 45.4±2.6 nM for NCI-H1975 EGFR D770_N771insSVD cells. TAS6417 also potently inhibits proliferation in other cell lines harboring activating mutations or acquired resistance mutations, with mean GI50 values of 1.92±0.21 nM to 7.12±0.60 nM. In contrast, the effect of TAS6417 on cell proliferation in normal human epidermal keratinocytes (NHEK-Neo), of which WT EGFR is implicates in the growth and survival, is moderate[1].

TAS6417 causes persistent tumor regression in vivo in EGFR exon 20 insertion-driven tumor models. TAS6417 inhibits mutant EGFR in tumors but not WT EGFR in skin tissues. TAS6417 prolongs survival of animals bearing lung cancer[1].

[1]. Hasako S, et al. TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Mol Cancer Ther. 2018 Aug;17(8):1648-1658.

리뷰

Review for TAS6417

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TAS6417

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.